Drug therapy in schizophrenia

Current Pharmaceutical Design

Volumn 10, Issue 18, 2004, Pages 2205-2217

  Ananth, J ^a,b   Parameswaran, S ^b   Hara, B ^b  

^a Metropolitan State Hospital   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Atypical antipsychotic drugs; Broad spectrum activity of atypical antipsychotic agents; Conventional antipsychotic drugs; Emergency treatment of acute psychosis; Long acting antipsychotic preparations; Maintenance treatment of schizophrenia; Treatment of acute psychosis

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RACLOPRIDE; REMOXIPRIDE; RISPERIDONE; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTINDOLE; SULPIRIDE; VALPROIC ACID; ZIPRASIDONE;

AGITATION; AGRANULOCYTOSIS; AKATHISIA; ANXIETY; BIPOLAR DISORDER; CLINICAL TRIAL; CONSTIPATION; DIABETES MELLITUS; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; ENURESIS; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPERTHERMIA; INSOMNIA; LIVER DYSFUNCTION; MONOTHERAPY; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR BLOCKING; RESPIRATION DEPRESSION; REVIEW; RHINITIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA; URINE RETENTION; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; SCHIZOPHRENIA;

EID: 3042587525     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384042     Document Type: Review

References (158)

1. Anden NE, Butcher SG, Corrodi H, Fuxe K, Ungerstedt U. Receptor activity and turnover of dopamine and noradrenaline after CAP drugs. Eur J Pharmacology 1970; 11: 303-14.
2. Seeman P, Wong M, Lee T. Dopamine receptor-block and nigral fiber-impulse blockade by major tranquilizers. Fed Pro 1974; 33:246
3. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481-83.
4. Seeman P, Wong M, Tedesco J. Tranquilizer receptors in rat striatum. Soc Neurosc Abst 1975; 1: 405.
5. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 262: 717-19.
6. Wong DF, Wagner HN Jr, Tune LE, Dannals RF, Pearlson GD, Links JM, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug naïve schizophrenics, Science 1986; 244: 1558-63.
7. 2 receptor increase in PET study of schizophrenia. Arch Gen Psychiatry 44:671, 1987.
8. 2 dopamine receptor in neuroleptic naïve schizophrenic patients. Arch Gen Psychiatry 1990; 47: 213-19.
9. 2 receptor occupancy in relation to clozapine serum concentration: A PET study in schizophrenic patients. Am J Psychiatry 1995; 152: 1444-49.
10. Crow T. The two syndrome concept: Origins and current status. Schizophr Bull 1985; 11: 471-86.
11. Levin S. Frontal lobe dysfunction in schizophrenia, II: Impairments of psychological and brain functions. J Psychiatr Res 1984; 18: 57-72.
12. Seidman LJ. Schizophrenia and brain dysfunction: An integration of recent neurodiagnostic findings. Psychiatr Bull 1983; 94: 195-238.
13. Merriam AE, Kay SR, Opler LA, Kushner SF, van Praag HM. Neurological signs and the positive-negative dimension in schizophrenia. Biol Psychiatry 1990; 28: 181-92.
14. Opler LA, Ramirez PM, Rosenkilde CE, Fiszbein A. Neurocognitive features of chronic schizophrenic patients. J Nerv Ment Dis 1991; 17: 638-40.
15. Andreasen NC, Rezai K, Alliger R, Swayze VW 2nd, Flaum M, Kirchner P, et al. Hypofrontality in neuroleptic-naïve patients and in patients with chronic schizophrenia. Arch Gen Psychiatry 1992; 49: 943-58.
16. Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF. Drug and sociotherapy in the aftercare of schizophrenic patients II: Two year relapse rates. Arch Gen Psychiatry 1974; 31: 603-08.
17. Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C. Important issues in the drug treatment of schizophrenia. Schizophr Bull 1980; 6: 70-87.
18. Kane JM. The current status of neuroleptic therapy. J Clin Psychiatry 1989; 50: 322-28.
19. Carpenter W, Heinrich DW, Wagnian AMI. Deficit and nondeficit forms of schizophrenia: The concept. Am J Psychiatry 1988; 145: 578-83.
20. Carpenter WT Jr, Heinrechs DW, Wagman AMI. Deficit and nondeficit forms of schizophrenia. The concept. Am J Psychiatry 1988; 145: 578-583.
21. Ayd FJ Jr. A survey of drug induced extrapyramidal reactions. JAMA 1961; 175: 102-08.
22. Kane J, Quitkin F, Rifkin A, Klein DF. Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate. Am J Psychiatry 1978; 135: 1539-42.
23. Von Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1978; 31: 67-72.
24. Rifkin A, Quitkin F, Klein DF. Akinesia:A poorly recognized drug induced extrapyramidal behavior disorder. Arch Gen Psychiatry 1975; 32: 642-74.
25. Jackson DM, Auden NE, Dahlstrom A. A functional effect of dopamine in the nucleus accumbens and in some other dopamine rich parts of the brain. Psychopharmacology (Berl) 1975; 45: 139-49.
26. 2 dopamine receptor antagonists induce fos and related proteins in rats striatal neurons. Neurosci 1990; 37: 287-94.
27. Miller JC. Induction of c-fos m RNA expression in rats striatum by neuroleptic drugs. J Neurochem 1990; 54: 1453-55.
28. Nguyen TV, Kosofsky BE, Birnbaum R, Cohen BM, Hyman SE. Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci USA 1992; 89: 4270-74.
29. Robertson GS, Fibiger HC. Neuroleptic increase c-fos expression in the forebrain: Contrasting effects of haloperidol and clozapine. Neuroscience 1992; 46: 315-28.
30. 3 receptor as a key target for antipsychotics. Clin Neuropharm 1992; 15(suppl 1):456A-457A.
31. 3 receptor m RNA levels in rat brain following antipsychotic treatment. Psychopharmacology (Berl) 1992; 106: 479-83.
32. 3) as a target for CAP drugs. Nature 1990; 347(6289): 146-51.
33. 4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610-14.
34. 1 receptors in schizophrenia revealed by PET. Nature 1997; 385: 634-44.
35. Seeman P. Receptor selectivities of atypical CAP drugs. In: Meltzer HY Ed, Novel Antipsychotic Drugs. New York, Raven Press 1992; 145-54.
36. 2 dopamine occupancy during treatment with conventional and atypical antipsychotics. Psychopharmacology 1989; 99: S28-S31.
37. 2 receptor occupancy in vivo by de novo atypical antipsychotic olanzapine: A123IBZM single photon emission tomography (SPECT) study: J Psychopharmacol 1996; 124: 148-53.
38. 3 receptors in rat brain. Eur J Pharnnacol 1992 Feb; 211: 189-94.
39. 3 dopamine receptors in rat brain and pituitary gland: A quantitative autoradiographic study. J Pharmacol Exp Ther 1993; 264: 991-1001.
40. Schwartz JC, Diaz J, Pilon C, Sokoloff P. Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res Brain Res Rev 2000 Mar; 31(2-3): 277-87.
41. 4 receptor elevated in schizophrenia. Nature 1993; 365: 441-45.
42. 4 receptors, Neuropsychopharmacol 1997; 16: 93-110.
43. 4 receptor m RNA in postmortem brains of schizophrenics and controls. Schizophr Res 1996; 20: 171-74.
44. 4 Dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacol 1995; 120: 365-68.
45. 3H]hydroxy-N, N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci USA 1993; 89: 8155-59.
46. 3 selective receptor ligand. Soc Neurosci Abstr 1993; 19: 1064.
47. 2, and serotonin2 pKi values. J Pharmacol Exp Ther 1989; 251: 238-46.
48. Goyer PF, Berridge MS, Morris ED, Semple WE, et al. PET Measurement of neuroreceptor occupancy by typical and atypical CAP drugs. J Nuclear Med 1996; 37: 1122-27.
49. Skarsfeldt T. Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 1995; 281: 238-94.
50. Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacol 1996; 14: 97-104.
51. Skarsfeldt T, Perregaard J. Sertindole a new neuroleptic with extreme selectivity on A10 versus A9 dopamine neurones in the rat. Eur J Pharmacol 1990; 182: 613-14.
52. Chiodo LA, Bunney BS. Typical and Atypical CAP drugs: Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983; 3: 1607-19.
53. Coward DM. General pharmacology of Clozapine. Br J Psychiatry 160:5, 1992.
54. Coward DM. The pharmacology of clozapine like, atypical antipsychotic drugs. In: Barnes T Ed, Antipsycholic Drugs and Their Side Effects. London, Academic Press 1993; 27.
55. Gerlach J, Behnke K, Heltberg J, Munk-Anderson E, Nielsen H. Sulpiride and haloperidol in schizophrenia: a double blind cross over study of therapeutic effect, side effects, and plasma concentrations. Br J Psychiatry 1995; 147: 283-88.
56. Jacob H, Beckmann H. Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J Neur Trans 1986; 65: 303-26.
57. Ogren SO, Florvall L, Hall H, Magnusson O, Angeby-Moller K. Neuropharmacological and behavioral properties of remoxipride in the rat. Acta Psychiatr Scand Suppl 1990; 358: 21-26.
58. White FJ, Wong RY. Differential effects of classical and atypical and antipsychotic drugs on A9 and A10 dopamine receptors. Science 1983; 221: 1054-57.
59. Bratfos O, Haug JO. Comparison of sulpiride and chlorpromazine in psychoses. A double blind multicenter Study. Acta Psychiatry Scand 1979; 135: 164-73.
60. Lewander T, Westerbergh SE, Morrison D. Clinical profile of remoxipride: A combined analysis of a comparative double blind multicenter trial programme. Acta Psychiatr Scand 1990; 82: 92-98.
61. Chouinard G. A placebo controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation. Acta Psychiatr Scand 82: 111-19, 1990.
62. 2 receptor blockcr, in acute schizophrenia: an open trial. Int Clin Psychopharmacol 1989; 4: 61-70.
63. 2-dopamine receptor occupancy by PET. Psychopharmacol 1988; 94: 1-7.
64. Hunziker F, Kunzle F, Schmutz J. Uber in 5-Stelung basisch substituierte 5H-dibenzo(b-c)-1-4-diazepine. Helv Chir Acta 1963; 46: 2337-2346.
65. Idanpaan-Heikkila J, Alliava E, Olkinuora M, Palva I. Clozapine and agranulocytosis. Lancet 1975; 2: 611.
66. Idanpaan-Heikkila J, Alliava E, Olkinuora M, Palva IP. Agranulocytusis during treatment with clozapine. Eur J Clin Pharmacol 1977; 11: 193-98.
67. Hippius H. The history of clozapine. Psychopharmacol (Berl) 1989; 99: 53-55.
68. Gelders YDG. Thymosthenic agent: A novel approach in the treatment of schizophrenia. Br J Psychiatry 1989; 155(suppl 5): 33-36.
69. Calabrese JR, Kimmel SE, Woyshville MJ, Rapport DJ, Faust CJ, Thompson PA, et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153: 759-64.
70. Antonacci DJ, Swartz CM. Clozapine treatment of euphoric mania. Ann Clin Psychiatry 1995; 7: 203-06.
71. Zarate CA Jr, Toben M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry 1995; 56: 411-17.
72. Zarate CAJr, Tohen M, Banov MD, Weiss MK, Cole JO. Is clozapine a mood stabilizer? J Clin Psychiatry 1995; 56: 108-12.
73. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158: 503-10.
74. Weller M, Kornhuber J. Clozapine induced neuroleptic malignant syndrome: another inconclusive case report. Aust N Z J Med 1996; 26: 232-33.
75. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PA. Biochemical profile of risperidone. J Pharmacol Exp Ther 1992; 24: 661-70.
76. Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 1988; 244(2):685-93.
77. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. Risperidone compared with new and reference antipsychotic drugs: In vivo and in vitro receptor binding. Psychopharmacol 1996; 124: 57-73.
78. Land W, Salzman C. Risperidone: A novel antipsychotic medication. Hosp Com Psychiatry 1994; 45: 434-35.
79. 2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride - an 1231-IBZ single photon emission tomography (SPECT) study. Psychopharmacol 1995; 117: 55-61.
80. Casey DE. Serotonergic and dopaminergic aspects of neuroleptic induced extrapyramidal syndromes in nonhuman primates. Psychopharmacol 1993; 112: S55-S59.
81. Casey DE. Behavioral effects of sertindole, risperidone, clozapine and haloperidol in cebus monkeys. Psychopharmacol 1996; 124: 134-40.
82. Stathis P, Antoniou K, Papadopoulou-Daifotis Z, Rimikis MN, Varonos D. Risperidone: A novel antipsychotic with many " atypical" properties? Psychopharmacol 1996; 127; 181-86.
83. 2 receptors. Int Clin Psychopharmacol 1995; 10: 19-30.
84. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 15: 825-35.
85. Casey DE, Hansen TE. Schizophrenia Pharmacology: risperidone and clozapine. In: Jefferson JW, Griest JH Eds, The Psychiatric Clinics of North America: Annals of Drug Therapy. Philadelphia, WB Saunders 1995; 119-49.
86. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: A multinational, multicentre, double blind parallel group study versus haloperidol. Br J Psychiatry 1995; 166: 712-26.
87. Tarsy D. Risperidone and neuroleptic malignant syndrome. JAMA 1996; 75: 446.
88. Webster P, Wijeratne C. Risperidone induced neuroleptic malignant syndrome. Lancet 1994; 344: 1705.
89. Dave M. Two cases of risperidone induced neuroleptic malignant syndrome. Am J Psychiatry 1995; 152: 1233-34.
90. Meterissian G. Risperidone-induced neuroleptic malignant syndrome: A case report and review. Can J Psychiatry 1996; 41: 52-54.
91. Bonwickz RJ, Hopwood MJ, Morris PL. Neuroleptic malignant syndrome and risperidone: A case report. Aust NZ J Psychiatry 1996; 30: 419-21.
92. Mesotten F, Suy E, Pietquin M, Burton P, Heylen S, Gelders Y. Therapeutic effect and safety of increasing doses of risperidone in psychotic patients. Psychopharmacol 1989; 99: 449.
93. Chakrabarti JK, Horsman L, Hotten TM, Pullar IA, Tupper DE, Wright FC. 4-Piperazinyl-10H-thieno[2, 3-b][1, 5]benzodiazepines as potential neuroleptics. J Med Chem 1980; 23(8): 878-84.
94. Moore NA, Tye NC, Axton MS, Risius FC. The behavioral Pharmacology of olanzapine: A novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 1992; 262: 545-51.
95. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacol 1996; 14: 87-96.
96. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, et al. Binding of typical and atypical antipsychotic agents to 5 hydroxytryptamine-6 and 5 hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994; 268: 1403-10.
97. Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P-450 CYP2C9, CYP2C19, CYP2D6, and CYP3A. Br J Clin Pharmacol 1996; 41: 181-86.
98. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. The olanzapine versus placebo and haloperidol: acute phase results of the North American double blind olanzapine trial. Neuropharmacol 1996; 14: 111-23.
99. Fulton B, Goa KL. Olanzapine: A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychosis. Drugs 1997; 53: 282-98.
100. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl) 1993; 112(2-3): 285-92.
101. Goldstein JM, Litwin LC, Sutton EB, Malick JB. Seroquel: electrophysiological profile of a potential atypical antipsychotic: Psychopharmacol 1993; 112: 293-98.
102. Ellenbrook BA, Lubbers LJ, Cools AR. Activity of seroquel in animal models for atypical properties of antipsychotics:A comparison with clozapine. Neuropharmacol 1996; 15: 406-16.
103. Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 2000; 15(3): 121-31.
104. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997; 96: 265-273.
105. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, et al. Ziprasidone (CP-88, 059): A new antipsychotic with combined dopamine and scrotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275(1): 101-13.
106. Arnt J. Differential Effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol 1995; 283(1-3): 55-62.
107. Fischman AJ, Bonab AA, Babich JW, Alpert NM, Rauch SL, Elmaleh DR, et al. Positron emission tomographic analysis of central 5-hydroxytryptamine 2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidoile. J Pharmacol Exp Ther 1996; 279: 939-47.
108. 2 receptors by the neuroleptic ziprasidone (CP-88, 059-01) determined by positron emission tomography. Psychopharmacol 1996; 124: 141-47.
109. Keck PE Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, et al. Ziprasidone 20 and 60 mg twice daily in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacol (Berl) 1998; 140: 173-184.
110. Daniel DG, Zimbroff DL, Polkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80mg/day and 160mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999, 20: 491-505.
111. 2 receptor antagonist activity, J Pharmacol Exp Ther 1995; 274: 329-336.
112. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63(9): 763-71.
113. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone vs. Placebo in Patients With Schizophrenia and Schizoaffective Disorder. Arch Gen Psychiatry 2003; 60(7): 681-90.
114. Kelland M, Freeman A, Chido L: Serotoninergic afferent regulation of the basic physiology and pharmacological responsiveness of strionigral neurons. J Pharmacol Exp Ther 1990; 253(2): 803-811.
115. Iyer R, Bradberry C: Serotonin mediated increase in prefrontal cortex dopamine release. Pharmacological characterization. J Pharmacol Exp Ther 1996; 27: 40-47.
116. Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, et al. gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem 1995; 65(6): 2652-62.
117. Grima G, Benz B, Parpura V, Cuenod M, Do KQ. Dopamine-induced oxidative stress in neurons with glutathione deficit Emplication for schizophrenia Schizophr Res 2003; 62: 213-224.
118. Concato J, Shah N, Horwitz RI. Randomized controlled trials, observational studies, and the hierarchy of research designs. New Engl J Med 2002; 342: 1887-1892.
119. Kay SR, Fizbein A, Opler LA. The positive and negative symptom scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 262-276.
120. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW. A Canadian multi-center placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25-40.
121. Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993, 88: 395-402.
122. Min SK, Rhee CS, Kim CE, Kang DY. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double blind comparative trial. Yonsei Med J 1993, 34: 179-190.
123. Huttunen MO, Piepponen T, Rantanen H, Larmo I, Nyholm R, Raitasuo V. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand 1995; 91: 272-277.
124. Blin O, AzorinJM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol 1996, 16: 38-44.
125. Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, et al. Risperidone versus clozapine in the treatment of chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 1998, 155:499-504.
126. Nair NP. Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group. J Clin Psychopharmacol 1998, 18:103-110.
127. Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. The Risperidone Working Group. Schizophr Bull 1999, 25: 721-729.
128. Peuskens J, Bech P, Moller HJ, Bale R, Fleurot O, Rein W. Amisulpride vs. risperidone in file treatment of acute exacerbations of schizophrenia. The Amisulpiride Study Group. Psychiatr Res 1999, 88: 107-117.
129. Beasley CM Jr, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, Blin O, Beuzen JN. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997; 7(2): 125-37.
130. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative study. Am J Psychiatry 1997; 154: 457-465
131. Jakovljevic M, Dossenbach MR, Friedel P, Schausberger B, Grundy SL, Hotujac L, et al., and the Olanzapine HGCH study group. Olanzapine versus fluphenazine in the acute (6 week) treatment of schizophrenia. Psychiatria Danubina 1999, 11(1-2):3-11.
132. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (Quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42:233-246.
133. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997; 96: 265-273.
134. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high and low dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997; 54: 549-557.
135. Copolov DL, Link CG, Kowalcyk B. A multicenter, double-blind randomized comparison of quetiapine (ICI 204, 636, Seroquel) and haloperidol in schizophrenia. Psychol Med 2000; 30: 95-105.
136. Tandon R, Harrigan E, Zorn SH. Ziprasidone: a novel antipsychotic with unique pharmacological and therapeutic potential. J Serotonin Res 1997; 4: 159-177.
137. Leucht S, Pitschel-walz G, Abraham D, Kissling W. Effficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A metaanalysis of randomized, placebo controlled trials. Schizophr Res 1999; 35: 51-68.
138. Geddes J, Freemantle N, Harrison P, Bebbington P: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis BMJ 2000; 321: 1371-1376.
139. Davis JM, Chen N, Glick ID. A metaanalysis of the efficacy of second generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-564.
140. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, Tollefson GD. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17(5): 407-18.
141. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001; 158(5): 765-74.
142. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther. 2001; 23(11):1839-54.
143. Tandon R, Jibson M, Taylor SF, DeQuardo JR. Conceptual models of the relationship between positive and negative symptoms: Implications for pathophysiology and treatment. In: Shriqui C, Nasrallah HA Eds, Contemporary Issues in the Treatment of Schizophrenia. Washington, DC, American Psychiatric Press 1995; 109-124.
144. Miller DD, Tandon R. The Biology and Pathophysiology of Negative Symptoms. In: Keefe R, McEvoy J. Eds, Negative Symptom of Schizophrenia. Washington, DC, American Psychiatric Press 2000; 163-186.
145. Bilder RM. Neurocognitive impairment in schizophrenia and how it affects treatment options. Can J Psychiatry 1997; 42: 255-264.
146. Harvey PD, Keefe RSE. Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment. CNS Spectr 1997; 2: 41-55.
147. Meltzer HY. New drugs for the treatment of schizophrenia. Psychiatr Clin North Am 1993; 16: 365-385.
148. Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998; 32: 215-228.
149. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001; 158: 518-526.
150. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for tile treatment-resistant schizophrenic: a double blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796.
151. Salzman C. Use of benzodiazepines to control disruptive behavior in inpatients. J Clin Psychiatry 1988; 49(suppl): 13-15.
152. Guz L, Morales R, Sartoretto JN. The therapeutic effects of lorazepam in psychotic patients treated with haloperidol: A doubleblind study. Curr Ther Res 1972; 14: 767-774.
153. Davis JM. Overview: maintenance therapy in psychiatry: I. Schizophrenia. Am J Psychiatry 1975; 132(12): 1237-45.
154. Glazer WM, Morgenstern H, Doucette J. Race and tardive dyskinesia among outpatients at a CMHE. Hosp Community Psychiatry 1994; 45(1): 38-42.
155. Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophr Bull 1993; 19(2): 303-315.
156. Ito C. Analysis of overall gene expression induced by amphetamine and phencyclidine: novel targets for the treatment of drug psychosis and schizophrenia. Curr Pharm Design 2002; 8(2): 147-53.
157. Luedtkea RR, Mach RH. Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders. Curr Pharm Design 2003; 9(8): 643-71.
158. Salerno L, Sorrenti V, Di Giacomo C, Romeo G, Siracusa MA. Progress in the development of selective nitric oxide synthase (NOS) inhibitors. Curr Pharm Design 2002, 8(3): 177-200.